{"meshTagsMajor":["Ampulla of Vater"],"meshTags":["Administration, Oral","Adult","Ampulla of Vater","Antineoplastic Combined Chemotherapy Protocols","Combined Modality Therapy","Common Bile Duct Neoplasms","Cyclophosphamide","Humans","Lymphatic Metastasis","Male","Neoplasm Recurrence, Local","Radiotherapy Dosage","Tegafur","Uracil"],"meshMinor":["Administration, Oral","Adult","Antineoplastic Combined Chemotherapy Protocols","Combined Modality Therapy","Common Bile Duct Neoplasms","Cyclophosphamide","Humans","Lymphatic Metastasis","Male","Neoplasm Recurrence, Local","Radiotherapy Dosage","Tegafur","Uracil"],"organisms":["9606"],"publicationTypes":["Case Reports","English Abstract","Journal Article"],"abstract":"A 38-year-old male patient underwent a pylorus-preserving pancreatoduodenectomy for an ampullary carcinoma of the papilla of Vater. One year after surgery a regular examination with CT and an echogram revealed a solitary recurrent tumor at a lymph node near the superior mesenteric artery. He was treated with radiotherapy at a total of 60 Gy and chemotherapy with UFT at 300 mg/day daily and oral administration of cyclophosphamide at 50 mg/day every other day. Four months after the initiation of the therapy the tumor had completely disappeared and the objective response was evaluated as a CR. The patients is now disease-free and continues to be treated with oral UFT and cyclophosphamide on an outpatient basis.","title":"[A case of recurrent ampullary carcinoma of the papilla of Vater, in which a complete response was induced by combination therapy using radiotherapy and oral chemotherapy employing UFT and cyclophosphamide].","pubmedId":"10553424"}